无结构染色体异常风险增加的妊娠中亚显微染色体异常的频率:系统综述与Meta分析
该系统综述与Meta分析检索EMBASE、PubMed、Web of Science和CENTRAL数据库(2016年6月3日),纳入因高龄或父母焦虑行产前侵入性检测的胎儿,汇总10项最大研究共10614例胎儿,估计致病性亚显微染色体异常频率为0.84%(95%CI 0.55-1.30%),并分析其发病年龄与外显率。
要点
- 因高龄或父母焦虑行侵入性检测的胎儿中,致病性临床显著亚显微染色体异常汇总估计为0.84%(95%CI 0.55-1.30%)。
- 早发型综合征疾病检出率为0.37%(95%CI 0.27-0.52%),易感性拷贝数变异为0.30%(95%CI 0.14-0.67%),晚发型疾病为0.11%(95%CI 0.05-0.21%)。
- 亚显微染色体异常所致早发型综合征疾病患病率计算为1:270;所有孕妇相关染色体异常风险高于1/180,36岁以下孕妇亚显微致病性异常风险高于唐氏综合征。
核心结论
- 该系统综述显示,一般妊娠人群中相当比例的胎儿携带亚显微致病性拷贝数变异。
- 基于这些数据,所有女性应被告知所有致病性染色体异常的个人风险,而不仅限于常见三体。
研究设计与样本
- 系统文献综述与Meta分析,检索EMBASE、PubMed、Web of Science和CENTRAL数据库,检索日期为2016年6月3日。
- 纳入因高龄或父母焦虑行产前侵入性检测的胎儿中致病性亚显微拷贝数变异患病率的相关全文文献。
- Meta分析基于10项最大研究(n>300)的汇总队列共10614例胎儿,总相关研究为19项。
- 亚显微发现发病年龄/外显率分析基于8篇论文报告的10314例胎儿,这些论文提供了可评估发现的异常病例全部必要细节。
主要发现
- 因高龄或父母焦虑行侵入性检测的胎儿中,致病性临床显著亚显微异常汇总估计为0.84%(95%CI 0.55-1.30%)。
- 早发型综合征疾病检出率为0.37%(95%CI 0.27-0.52%),易感性拷贝数变异为0.30%(95%CI 0.14-0.67%),晚发型疾病为0.11%(95%CI 0.05-0.21%)。
- 亚显微染色体异常所致早发型综合征疾病患病率计算为1:270。
- 将亚显微异常风险加至显微镜下染色体异常个体风险后,所有孕妇相关染色体异常风险高于1/180,36岁以下孕妇亚显微致病性异常风险高于唐氏综合征。
关键数值与推荐
- 致病性临床显著亚显微异常汇总估计为0.84%(95%CI 0.55-1.30%)。
- 早发型综合征疾病检出率为0.37%(95%CI 0.27-0.52%)。
- 易感性拷贝数变异为0.30%(95%CI 0.14-0.67%)。
- 晚发型疾病为0.11%(95%CI 0.05-0.21%)。
- 亚显微染色体异常所致早发型综合征疾病患病率为1:270;所有孕妇相关染色体异常风险高于1/180。
临床怎么用
- 原文结论指出所有女性应被告知所有致病性染色体异常的个人风险,而不仅限于常见三体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To establish, based on a systematic literature review, the frequency of pathogenic submicroscopic chromosomal aberrations in fetuses that are not at increased risk for unbalanced structural chromosomal aberrations, with the aim of determining whether high-resolution testing for submicroscopic aberrations is beneficial in a general pregnant population. METHODS: EMBASE, PubMed, Web of Science and CENTRAL databases were searched systematically on 3 June 2016 for all relevant articles on the prevalence of pathogenic submicroscopic copy number variants (CNVs) in fetuses referred for prenatal invasive testing because of advanced maternal age (AMA) or parental anxiety (ANX). Relevant full-text articles were analyzed and the prevalence of submicroscopic CNVs was calculated based on the extracted data. Meta-analysis was conducted in a pooled cohort of 10 614 fetuses based on the 10 largest studies (n > 300) of a total of 19 that were relevant. RESULTS: Pooled estimate analysis indicated that 0.84% (95% CI, 0.55-1.30%) of fetuses that had invasive testing because of AMA/ANX carried a pathogenic clinically significant submicroscopic aberration. The onset/penetrance of submicroscopic findings was studied in 10 314 fetuses reported in eight papers that presented aberrant cases with all necessary details to allow assessment of the findings. The pooled estimates resulting from meta-analysis of the data indicated that an early-onset syndromic disorder was detected in 0.37% (95% CI, 0.27-0.52%) of cases, a susceptibility CNV was found in 0.30% (95% CI, 0.14-0.67%) and late-onset diseases were reported in 0.11% (95% CI, 0.05%-0.21%). The prevalence of early-onset syndromic disorders caused by a submicroscopic aberration was calculated to be 1:270. When the risk for submicroscopic aberrations is added to the individual risk for microscopic chromosomal aberrations, all pregnant women have a risk of higher than 1 in 180 for a relevant chromosomal aberration, and pregnant women under 36 years of age have a higher risk for submicroscopic pathogenic aberrations than for Down syndrome. CONCLUSION: This systematic review shows that a significant proportion of fetuses in a general pregnant population carry a submicroscopic pathogenic CNV. Based on these figures, all women should be informed on their individual risk for all pathogenic chromosomal aberrations and not only for common trisomies. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Srebniak MI, Joosten M, Knapen MFCM, et al. Frequency of submicroscopic chromosomal aberrations in pregnancies without increased risk for structural chromosomal aberrations: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018. PMID: 28556491. doi:10.1002/uog.17533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。